Allison S Betof

27PUBLICATIONS
143CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyPredictive and prognostic markersImmunogenetics (incl. genetic immunology)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (27)

|Aug 25, 2026
Outpatient Treatment-Related Toxicity After Hospital Discharge Among Patients Receiving Lifileucel for Advanced Melanoma.

|Jun 25, 2026
Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanoma.

|Jun 22, 2026
Immune checkpoint blockade augments lymphodepleting chemotherapy-induced antitumor immunity by expanding effector CD8+ T cell clones.

|Jan 10, 2026
Metastatic Uveal Melanoma Surveillance: A Delphi Panel Consensus.

Juan Alban, R Christopher Bowen, David A Reichstein

|Oct 15, 2025
Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors.

Ling Zhu, Yee-Ming M Cheung, Cherie Chiang

|Jul 10, 2025
Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma.

Elizabeth M Burton, Denái R Milton, Michael T Tetzlaff

Pageof 5

Frequent Collaborators

11 joint publications

Alexander Noor Shoushtari

8 joint publications

Michael Postow

7 joint publications

Jedd D Wolchok

5 joint publications

Ryan Sullivan